Related Experiment Video
Updated: May 12, 2026
03:53
Development of Multiplex Real-Time RT-qPCR Assays for the Detection of SARS-CoV-2, Influenza A/B, and MERS-CoV
Published on: November 10, 2023
Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID-19
Shin Watanabe1, Yosuke Shimizu1,2, Hiroyuki Sato1
1Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Pharmaceutical Statistics
|May 10, 2026
Summary
Platform trials for drug development face challenges from temporal shifts. Nonconcurrent control data can introduce bias, requiring robust statistical methods for reliable results in evolving COVID-19 landscapes.
Area of Science:
- Clinical Trials
- Biostatistics
- Epidemiology
Background:
- The COVID-19 pandemic accelerated platform trial adoption for efficient drug development.
- Platform trials evaluate multiple treatments concurrently but are susceptible to temporal shifts in patient populations, trial conduct, and standard of care.
- Nonconcurrent control (NCC) data can boost statistical power but risks bias if temporal shifts are not adequately addressed.
Purpose of the Study:
- To empirically evaluate temporal shifts in clinical outcomes within a real-world platform trial setting.
- To assess the operating characteristics of statistical methods using concurrent and nonconcurrent control data.
- To investigate the impact of evolving SARS-CoV-2 variants on platform trial data and control arm validity.
Main Methods:
- Utilized real-world data from the ACTIV-1 Immune Modulator platform trial.
- Employed resampling-based simulation studies using ACTIV-1 IM data.
- Conducted simulations under hypothetical scenarios modeling variant-driven temporal shifts in SARS-CoV-2.
- Analyzed clinical outcomes including time to recovery, clinical status, and mortality through Day 28.
Main Results:
- Empirical analyses indicated that simulation assumptions regarding temporal shifts and constant treatment effects may not reflect real-world platform trial complexities.
- Simulation studies demonstrated that even adjusted methods for utilizing NCC data can introduce significant bias in complex, evolving settings.
- Temporal shifts in clinical outcomes were observed, influenced by the changing landscape of SARS-CoV-2 variants.
Conclusions:
- Real-world evidence highlights the limitations of standard simulation assumptions in platform trials.
- Existing adjustment methods for nonconcurrent control data may be insufficient to mitigate bias in dynamic environments.
- There is a critical need for robust statistical methodologies to reliably integrate nonconcurrent control data and account for temporal shifts in platform trials.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:13Controls in Experiments
When conducting an experiment, it is crucial to have control to reduce bias and accurately measure the dependent variables. It also marks the results more reliable. Controls are elements in an experiment that have the same characteristics as the treatment groups but are not affected by the independent variable. By sorting these data into control and experimental conditions, the relationship between the dependent and independent variables can be drawn. A randomized experiment always includes a...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...